CS
ALLO icon

Candriam SCA’s Allogene Therapeutics ALLO Stock Holding History

Candriam SCA’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.01M Buy
4,336,296
+1,338,978
+45% +$2.94M 0.04% 299
2026
Q1 		$7.31M Buy
2,997,318
+691,674
+30% +$1.39M 0.04% 332
2025
Q4 		$3.16M Buy
+2,305,644
New +$3.04M 0.02% 439
2020
Q4 		– Sell
-66,561
Closed -$2.51M – 810
2020
Q3 		$2.51M Sell
66,561
-1,366
-2% -$51.5K 0.02% 464
2020
Q2 		$2.91M Buy
+67,927
New +$2.46M 0.03% 426

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Candriam SCA's ALLO Position: Q2 2026 in Review

Candriam SCA increased its Allogene Therapeutics (ALLO) stake by 45% in Q2 2026, buying an estimated $2.94M and bringing the position to 4,336,296 shares worth $9.01M. The position accounts for 0.04% of the portfolio, ranked #299.

Candriam SCA first reported a position in ALLO in Q2 2020 and has held it in 5 quarters since. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Candriam SCA held 4,336,296 shares of Allogene Therapeutics worth $9.01M as of Q2 2026.
  • Candriam SCA bought 1,338,978 Allogene Therapeutics shares in Q2 2026, an estimated $2.94M.
  • Allogene Therapeutics made up 0.04% of Candriam SCA's portfolio in Q2 2026, its #299 holding.
  • Candriam SCA first reported a position in Allogene Therapeutics in Q2 2020 and has held it in 5 quarters since.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.